Small Molecules

27 Sep 2019 BRILINTA Monotherapy in High-Bleeding Risk Patients Who Underwent PCI had Reduced Risk of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy in the TWILIGHT Trial
27 Sep 2019 Pfizer Announces Positive Top-Line Results from Second Pivotal Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis
25 Sep 2019 Salarius Pharmaceuticals Achieves Dose-Escalation Milestones in Ongoing Phase 1/2 Ewing Sarcoma and Phase 1 Advanced Solid Tumor Clinical Trials
25 Sep 2019 Galapagos initiates Phase 1 trial for second Toledo compound
25 Sep 2019 Linnaeus Therapeutics Announces FDA Clearance of Investigational New Drug Application for LNS8801
25 Sep 2019 OCTIMET Expands Ongoing Proof of Concept Study to Evaluate the Combination of Highly Selective MET Kinase Inhibitor OMO-1 with EGFR TKIs
25 Sep 2019 MC2 Therapeutics Announces Submission of New Drug Application to US FDA for Wynzora™ Cream (Calcipotriene 0.005% and Betamethasone Dipropionate 0.064%) for Treatment of Plaque Psoriasis
25 Sep 2019 Ocular Therapeutix™ Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Allergic Conjunctivitis
25 Sep 2019 UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer
25 Sep 2019 NORTHSEA THERAPEUTICS: NST doses first patient in Phase 2b clinical study of icosabutate in NASH (‘ICONA’)
24 Sep 2019 Vitrakvi® (larotrectinib) receives first tumor-agnostic approval in EU
24 Sep 2019 GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
24 Sep 2019 Auransa Presents New Preclinical Data on AU-409, a Novel, AI-Derived Drug Candidate for the Treatment of Hepatocellular Carcinoma
24 Sep 2019 Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise
24 Sep 2019 Preliminary results from Phase IIb Liproca® Depot dose-finding study show a strong maximum PSA decrease and sustained PSA reduction effect
24 Sep 2019 ESMO Annual Meeting 2019: Menarini Ricerche Presents the Preclinical Characterization of MEN1611, a Novel PI3K Inhibitor in Development for the Treatment of Breast Cancer
24 Sep 2019 Phoenix Molecular Designs Receives FDA Clearance to Begin Phase 1/1b Clinical Trial with PMD-026, a First-in-Class RSK Inhibitor, Targeting Advanced Breast Cancer
24 Sep 2019 Neurana Pharmaceuticals Announces Positive Topline Results from Phase 2 STAR Study of Tolperisone in Acute Muscle Spasms of the Back
24 Sep 2019 AVEO Oncology and EUSA Pharma Announce Presentation of Final PFS Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma
24 Sep 2019 Cerevel Therapeutics Announces Positive Results from a Phase 2 Study of Tavapadon in Patients with Early-stage Parkinson’s Disease
23 Sep 2019 Qtrilmet recommended for approval in EU by CHMP for the treatment of type-2 diabetes
20 Sep 2019 XORTX Announces Positive Phase 2 Results in Type 2 Diabetic Nephropathy (T2DN)
20 Sep 2019 Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
20 Sep 2019 Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
20 Sep 2019 Aerie Pharmaceuticals Receives Positive CHMP Opinion for Rhokiinsa® in the European Union

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up